Two scientific posters presented at this week’s 2025 Global Contact Lens Symposium (GSLS) reveal new research surrounding CooperVision advancements that are shaping the contact lens category. They profile aspects of the unique optical design used in MyDay Energys® and Biofinity Energys® brands for digital device users, as well as the company’s innovative Binocular Progressive System™ for presbyopes that is part of the MyDay® and clariti® 1 day product families.
“While we conduct and support a sizable range of foundational studies every year, we also prioritize research that helps eye care professionals (ECPs) have a deeper understanding of how the contact lenses they fit everyday work in practice on their patients. This helps support confidence among prescribers, ideal patient experiences, and practice success. It’s the type of practical scientific evidence that the profession has come to expect from a partner like CooperVision,” said Francis Erard, the company’s Vice President of Research & Development.
A Closer Look at DigitalBoost™ Technology
CooperVision designed DigitalBoost™ Technology to help with eye tiredness associated with digital device use by delivering a +0.3D boost in an innovative single vision aspheric lens design.*1,2 The authors of Performance of Two Contact Lens Designs in a Clinical Setting and Through Computational Optical Modelling (Walsh K, et al.) examined two aspects of MyDay Energys® performance, both of which help account for the popularity of that lens as well as Biofinity Energys®.
A team from the Centre for Ocular Research & Education (CORE) at the University of Waterloo evaluated distance visual acuity (VA) and subjective responses among 77 subjects in a multi-center, bilateral wear, one-week dispensing study. Compared to MyDay® sphere, there was no difference in binocular logMAR high contrast distance VA with MyDay Energys®. In addition, MyDay Energys® was rated more comfortable than MyDay® sphere on average, with notable end-of-day differences favoring MyDay Energys®.
In parallel, a team from the James C. Wyant College of Optical Sciences at the University of Arizona used computational optical modelling to visualize the image quality between the two lens designs at different vergences. Three-dimensional scene analysis showed better image quality at near and intermediate distances for MyDay Energys® compared to MyDay® sphere, with similar distance image quality.
Binocular Progressive System™ Allows ECPs to Fit a Wide Range of Patients with Presbyopia
Since dioptric power changes across multifocal contact lens optic zones create simultaneous foci that reduce contrast and affect perceived vision quality, researchers sought to assess the associated impact of pupil size, which varies by individual, and under different luminance levels. Influence of Pupil Size on Vision Performance and Visual Satisfaction with a Daily Disposable Multifocal Contact Lens System (Marullo R, et al.) enrolled 45 presbyopes with varied pupil sizes (2.3 mm at 250cd/m2 to 6.6 mm at 2.5cd/m2) fit into MyDay® daily disposable multifocal with the Binocular Progressive System™ contact lenses. Investigators measured distance binocular high contrast visual acuity (BHCVA) under high and low illumination, distance binocular low contrast visual acuity (BLCVA) under high illumination, near BHCVA and near BHLCA under medium illumination, as well as subjective vision satisfaction scores at distance and near. No significant correlations were found between visual acuity and pupil size regardless of viewing distance, contrast, and luminance. Correlations between vision metrics (visual acuity and vision satisfaction) and pupil size after one week of wear were weak or very weak in every environmental condition. The findings indicate that the Binocular Progressive System™ effectively corrects for presbyopia independent of pupil size, supporting that the latest MyDay® multifocal and clariti® 1 day multifocal offerings give ECPs the ability to fit a wide spectrum of patients.
“The caliber of eye care is constantly increasing around the globe, as are expectations among patients and ECPs alike. CooperVision believes that reinforcing everyday clinical decisions with sound evidence will continue to become more critical, and why we are dedicated to advancing ocular science through the research we conduct and support though our partnerships,” said Erard.
A full schedule of events and presentations for GSLS 2025, which takes place in Las Vegas from January 15-18, 2025, is available at gslsymposium.com.
